PDCD1 and non-small cell lung carcinoma: The pioneer phase 3 randomized trials were CheckMate 017 and CheckMate 057, which evaluated nivolumab (an anti–PD–1 antibody) for previously treated squamous and non–squamous NSCLC, respectively, and published their results in 2015 (13, 33).